B · Normal
September 10th: Insilicon Intelligent’s AI-driven innovative drug candidate Rentosertib has completed the enrollment and administration of the first patient in the Phase III clinical trial GENESIS-IPF-3 for idiopathic pulmonary fibrosis.
🕐 2026-09-10 08:20
#clinical trial
Save as Image Generate a beautiful long image to share on Moments or in group chats Generate now ⬇
← Back to Telegraph

Related telegraphs

[Four-connected Nanhua Bio: Cell therapy-related technologies and products are s 09-22 18:20 [Yahong Pharmaceutical: APL-2501 has completed the enrollment of the first subje 09-22 17:43 On September 22, Roche’s ENICEPATIDE met the two primary endpoints of its Phase 09-22 13:07 [AI pharmaceutical company Iambic backed by NVIDIA submits U.S. IPO application] 09-22 08:39 [Shenlian Bio: The Phase II clinical trial of UB-221 for the treatment of chroni 09-20 15:32 [State Food and Drug Administration: Establishing a market exclusivity period sy 09-20 10:54

Comments

0/500
Captcha (click to refresh)
No comments yet